Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020

NEXT STORY
Curetis N.V. Informs on OpGen’s Fourth Quarter and Full Year 2019 Financial Results and Business Update
PREV STORY
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Clene Reports Third Quarter 2021 Operating and Financial Highlights

author_avatar
NASDAQ Market News

Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BERKELEY, Calif., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced ...

author_avatar
NASDAQ Market News

Celsion Announces Positive Data from the OVATION Study – An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients

LAWRENCEVILLE, N.J., July 25, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced data from ...

author_avatar
NASDAQ Market News